Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy

Απλή σελίδα τεκμηρίου
dc.contributor.authorTzaida, O.en
dc.contributor.authorGogas, H.en
dc.contributor.authorDafni, U.en
dc.contributor.authorKyroudi, A.en
dc.contributor.authorPapaspyrou, I.en
dc.contributor.authorKyriakou, V.en
dc.contributor.authorMalamou-Mitsi, V.en
dc.contributor.authorAlamani, M.en
dc.contributor.authorSkopa, C.en
dc.contributor.authorKostopoulos, I.en
dc.contributor.authorKastritis, E.en
dc.contributor.authorPectasides, D.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorAravantinos, G.en
dc.contributor.authorFountzilas, G.en
dc.contributor.authorArapantoni-Dadioti, P.en
dc.date.accessioned2015-11-24T19:17:34Z
dc.date.available2015-11-24T19:17:34Z
dc.identifier.issn1423-0232-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21791
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration & dosageen
dc.subjectBreast Neoplasms/drug therapy/*genetics/metabolism/mortalityen
dc.subjectChemotherapy, Adjuvanten
dc.subjectCombined Modality Therapyen
dc.subjectCyclophosphamide/administration & dosageen
dc.subjectDisease-Free Survivalen
dc.subjectEpirubicin/*administration & dosageen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosageen
dc.subjectGenes, erbB-1/*geneticsen
dc.subjectHumansen
dc.subjectImmunohistochemistryen
dc.subjectMethotrexate/administration & dosageen
dc.subjectMiddle Ageden
dc.subjectPaclitaxel/*administration & dosageen
dc.subjectPredictive Value of Testsen
dc.subjectPrognosisen
dc.titleEvaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyen
heal.abstractBACKGROUND: To assess the prognostic and predictive significance of HER-1/EGFR protein levels in high-risk patients with breast cancer treated with dose-dense sequential adjuvant chemotherapy. METHODS: 595 high-risk breast cancer patients were treated with adjuvant anthracycline-based dose-dense sequential chemotherapy (E-CMF vs. E-T-CMF). Disease-free survival (DFS) was the primary end point. HER-1/EGFR was assessed by immunohistochemistry (IHC) in 312 patients. RESULTS: HER-1/EGFR expression was detected in 54 of 312 patients (17%). Positive expression of HER-1/EGFR was significantly associated with negative receptor status (52 vs. 17%, p < 0.001), worse histological grade (70 vs. 45%, p = 0.001), HER-2 overexpression (46 vs. 27%, p = 0.01) and positive p53 expression (48 vs. 19%, p < 0.001). With a median follow-up of 7 years, the total number of relapses was 105 (34%), and the total number of deaths 69 (22%). The analysis for DFS provides significant evidence that the HER-1/EGFR effect on the risk of disease progression was different according to treatment (interaction p = 0.02). Regarding overall survival, a trend towards a significant difference for an interaction of HER-1/EGFR and treatment was found (p = 0.07). CONCLUSION: The present study demonstrated a differential effect of positive HER-1/EGFR expression in the two treatment groups, with HER-1/EGFR being a negative prognostic marker in the absence of paclitaxel.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1159/000113148-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/18187961-
heal.identifier.secondaryhttp://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=000113148&Ausgabe=234514&ProduktNr=223857&filename=000113148.pdf-
heal.journalNameOncologyen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2007-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ